This trial has completed recruitment on this platform, and is no longer accepting new referrals.
This trial is evaluating a potential therapy to prevent COVID-19 infection in people who live/work in an environment that may put them at risk for possible exposure to COVID-19.
Trial ID: NCT04859517
The purpose of the EVADE study is to evaluate an investigational medicine called ADG20, a monoclonal antibody, in individuals (18 years or older) who have no known history of COVID-19 and who have not received the COVID-19 vaccine.
Researchers want to see if ADG20 can prevent COVID-19. If you have questions about this study or would like to prescreen over the phone, please call (855) 720-1412.
You will be asked to attend study visits with a doctor or nurse, some of which will be in person and others over the telephone, and you will need to collect some information at specific timepoints at home. If you are eligible to enroll, you will receive a single injection of either the study medication or placebo. There will then be follow-up visits over the next 14 months (either in person or on the phone) to track laboratory and health measurements. The doctor’s office conducting the study will be able to provide you with more information about the study requirements.
You will need to travel to one of the study clinics taking part in this clinical trial.
Sites are located in the cities/states identified with the red pin: